1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow Breast Cancer Invasive: new trials by email Literature Review of Breast Cancer Invasive trials Research Report on Breast Cancer Invasive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel - Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer | Phase 3 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 160 | 2024-01-17 | 2026-10-27 |
| Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer pyrotinib - Breast Cancer Invasive | Phase 3 | Recruiting | RenJi Hospital | 488 | 2023-06-01 | 2025-11-18 |
| Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial) Leuplin or zoladex - Breast Cancer Invasive | Phase 3 | Unknown | Seoul National University Hospital | 224 | 2018-09-03 | 2023-12-04 |
Breast Neoplasms (1)
Breast Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
pyrotinib (2) · Cyclophosphamide (1) · Doxorubicin (1) · Epirubicin (1) · Goserelin (1) · Leuprolide (1) · Paclitaxel (1)
RenJi Hospital (1) · Seoul National University Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
China (2) · South Korea (1)
Chang Gong, Prof (1) · Wenjin Yin, M.D. (1) · Wonshik Han (1)